Glycine and clozapine: potential relevance for the treatment of Parkinson's disease

Click to increase image sizeClick to decrease image size

Author contributions

P Huot wrote the first draft of the manuscript and S Maddaford reviewed and critiqued the manuscript.

Financial disclosure

S Maddaford is President and CSO of Talon Pharmaceuticals. P Huot has had research support from Parkinson Canada, Fonds de Recherche Québec – Santé, Parkinson Québec, Healthy Brains for Healthy Lives, the Natural Sciences and Engineering Research Council of Canada, the Michael J Fox Foundation for Parkinson's Research, the New Frontiers in Research Fund, the Canadian Institutes of Health Research and the Weston Brain Institute. P Huot has received payments from Neurodiem, AbbVie, Sunovion, Throughline Strategies, Sanford Burnham Prebys and adMare BioInnovations and is a Scientific Advisor to Talon Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

Talon Pharmaceuticals is developing glycine-based therapies for Parkinson's disease. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.